FindMyKOL
Clinical trialNCT06024096CompletedPhase 4Interventional

Systems Biological Assessment of Statin Effect on Vaccine Responses

NCT06024096 is a phase 4 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is completed. It studies Atorvastatin and Quadrivalent seasonal influenza vaccine in Vaccine Response. The registry lists an enrollment of 63 participants at 1 site in 1 country. The registry lists a start date of 20 Sept 2023 and a primary completion date of 16 Dec 2024. One of its registered investigators has a FindMyKOL profile.

SponsorEmory University →Enrollment63Vaccine Response
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06024096
FieldValue
Registry IDNCT06024096
StatusCompleted
PhasePhase 4
Study typeInterventional trial
Lead sponsorEmory University
Enrollment63
Registered sites1
Countries1
ConditionsVaccine Response
DrugsAtorvastatin and Quadrivalent seasonal influenza vaccine
Start20 Sept 2023
Primary completion16 Dec 2024
Study completion16 Dec 2024
Last update posted14 Jan 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand how this medication affects long-lasting immune responses to vaccines. The researchers will study the immune response to the influenza vaccine in the blood (where antibodies are). The team will also look at how statin therapy affects the bacteria that live in the gut by collecting stool samples. To be in this research, participants must be adults willing to receive vaccines.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States1 site
  • Hope Clinic

    Atlanta

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 siteGA1HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atorvastatin →Quadrivalent seasonal influenza vaccine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06024096

Each answer restates registry values shown on this page.

What is NCT06024096?

NCT06024096 is a phase 4 interventional trial sponsored by Emory University. It studies Atorvastatin and Quadrivalent seasonal influenza vaccine in Vaccine Response.

Who leads NCT06024096?

The registry names Daniel S. Graciaa, MD, MPH, MSc (principal investigator, Emory University), Nadine Rouphael, MD (principal investigator, Emory University), Varun Phadke, MD (principal investigator, Emory University) and 1 more official as overall officials.

Where does NCT06024096 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06024096 study?

The registered drug and biological interventions are Atorvastatin and Quadrivalent seasonal influenza vaccine.

When did NCT06024096 end?

The registry lists a primary completion date of 16 Dec 2024 and a study completion date of 16 Dec 2024. The sponsor last updated the record on 14 Jan 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.